Sanofi Price to Free Cash Flow Ratio 2010-2023 | SNY

Historical price to free cash flow ratio values for Sanofi (SNY) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Sanofi Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2024-05-17 48.67 13.70
2023-12-31 47.73 $3.55 13.43
2023-09-30 51.49 $4.11 12.52
2023-06-30 51.74 $5.51 9.38
2023-03-31 50.34 $4.11 12.24
2022-12-31 44.80 $4.11 10.89
2022-03-31 45.96 0 0.00
2021-09-30 43.16 0 0.00
2021-03-31 42.66 0 0.00
2020-09-30 43.27 0 0.00
2020-03-31 36.39 0 0.00
2019-09-30 38.56 $2.66 14.51
2019-03-31 35.37 $1.78 19.82
2018-03-31 30.56 $2.66 11.50
2017-12-31 32.79 $2.66 12.34
2017-09-30 37.97 $2.55 14.91
2017-06-30 36.53 $2.78 13.14
2017-03-31 33.37 $2.55 13.11
2016-12-31 29.83 $2.55 11.71
2016-09-30 28.17 $-1.09 0.00
2016-06-30 30.87 $-0.44 0.00
2016-03-31 28.41 $-0.78 0.00
2015-09-30 33.58 $-1.76 0.00
2015-06-30 35.04 $1.09 32.29
2014-06-30 36.43 $1.08 33.64
2013-06-30 34.07 $4.91 6.93
2012-06-30 24.14 $4.15 5.82
2012-03-31 23.66 $4.13 5.72
2011-12-31 22.31 $4.13 5.40
2011-09-30 20.02 $4.23 4.73
2011-06-30 24.52 $4.24 5.78
2011-03-31 20.78 $4.23 4.91
2010-12-31 19.02 $4.23 4.49
2010-09-30 19.62 $3.64 5.40
2010-06-30 17.74 $3.51 5.06
2010-03-31 21.27 $3.64 5.85
2009-12-31 22.35 $3.64 6.15
2009-09-30 21.03 0 0.00
2009-06-30 16.79 $1.87 8.98
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $123.116B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Pfizer (PFE) United States $162.291B 20.17
Innoviva (INVA) United States $0.998B 7.01